Cargando…
A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study
COVID-19 is a global pandemic, with over 50 million confirmed cases and 1.2 million deaths as of November 11, 2020. No therapies or vaccines so far are recommended to treat or prevent the new coronavirus. A novel traditional Chinese medicine formula, Taiwan Chingguan Yihau (NRICM101), has been admin...
Autores principales: | Tsai, Keng-Chang, Huang, Yi-Chia, Liaw, Chia-Ching, Tsai, Chia-I, Chiou, Chun-Tang, Lin, Chien-Jung, Wei, Wen-Chi, Lin, Sunny Jui-Shan, Tseng, Yu-Hwei, Yeh, Kuo-Ming, Lin, Yi-Ling, Jan, Jia-Tsrong, Liang, Jian-Jong, Liao, Chun-Che, Chiou, Wen-Fei, Kuo, Yao-Haur, Lee, Shen-Ming, Lee, Ming-Yung, Su, Yi-Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676327/ https://www.ncbi.nlm.nih.gov/pubmed/33249281 http://dx.doi.org/10.1016/j.biopha.2020.111037 |
Ejemplares similares
-
Treating COVID-19 with NRICM101 and NRICM102 – Author’s reply
por: Lin, Sunny Jui-Shan, et al.
Publicado: (2022) -
Treating COVID-19 with NRICM101 and NRICM102 – Author’s reply 3
por: Tseng, Yu-Hwei, et al.
Publicado: (2022) -
Treating COVID-19 with NRICM101 and NRICM102 – Author’s reply 2
por: Lee, Ming-Yung, et al.
Publicado: (2022) -
NRICM101 ameliorates SARS-CoV-2–S1-induced pulmonary injury in K18-hACE2 mice model
por: Wei, Wen-Chi, et al.
Publicado: (2023) -
Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis
por: Wei, Wen-Chi, et al.
Publicado: (2022)